Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.
about
Clinical utility and patient considerations in the use of the sitagliptin-metformin combination in Chinese patientsThe durability of sitagliptin in elderly patients with type 2 diabetes.Factor Analysis of Changes in Hemoglobin A1c After 12 Months of Sitagliptin Therapy in Patients With Type 2 Diabetes.Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitus.Canagliflozin: a review of its use in patients with type 2 diabetes mellitus.Antihyperglycaemic therapies and cancer risk.Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.A review of gliptins for 2014.Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.Sitagliptin: A Review in Type 2 Diabetes.Rhabdomyolysis and AKI with Atorvastatin and Sitagliptin Use in the Setting of Low 25-Hydroxyvitamin D Levels.Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study.Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes.SDF-1α (Stromal Cell-Derived Factor 1α) Induces Cardiac Fibroblasts, Renal Microvascular Smooth Muscle Cells, and Glomerular Mesangial Cells to Proliferate, Cause Hypertrophy, and Produce Collagen.GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose.Design, Synthesis and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel DPP-4 Inhibitors.A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone.
P2860
Q28083144-C9968658-4ED0-44ED-855C-CEEEE87DB6E5Q34511545-9E99BEB3-800D-4A3A-939E-3737281C7365Q36856980-2E325369-0CD3-42D3-85BE-3675DE23A3E3Q37227397-8C5D1C1D-D913-4D4A-8D3F-2D82A808A6C9Q38212007-967DC161-7387-4542-9EC4-58196E213803Q38250719-9B1FABBC-B8F9-4B1B-9902-C9C87B89DE20Q38261573-BC17579D-7347-431A-B823-5F1C7BCAE802Q38266290-1AC3C76D-92C7-4726-AA7F-5B6DF3F329F0Q38335751-54182963-4C79-44EE-BA22-1F2E2F9E588DQ38902321-37230511-758F-472C-B719-A56F25C7EF75Q39063447-B0F938C1-31C7-4338-8761-F0175D13B0F0Q39081543-8466741C-996B-4423-9E65-811F9725C71CQ39434470-FE4B3F50-F84C-488F-B3DC-875837E54026Q40492085-5103FAF9-71DA-4689-B428-81AFB936D8A5Q42876331-CBBFDB1F-2BDA-428E-B397-45552EB8A8B7Q47121177-5C9AD59E-C724-4C0B-80F1-088609E4D2E2Q49414493-7DE0A44A-828F-40ED-B1E3-108739CDE9FCQ50997819-82D86EBE-C0E9-42AE-9118-EC156B500CD9Q51226655-6434F68B-F9A8-4415-B5CF-AFEA60FEA30A
P2860
Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.
@en
type
label
Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.
@en
prefLabel
Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.
@en
P2860
P1433
P1476
Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.
@en
P2860
P2888
P304
P356
10.1007/S40265-013-0169-1
P577
2014-02-01T00:00:00Z
P6179
1008322827